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The so-called shock and kill therapies aim to combine HIV-1 reactivation by
latency-reversing agents (LRA) with immune clearance to purge the HIV-1 reservoir.
The clinical use of LRA has demonstrated detectable perturbations in the HIV-1
reservoir without measurable reductions to date. Consequently, fundamental questions
concerning the limitations of the recognition and killing of LRA-reactivated cells by
effector cells such as CD8+ T cells remain to be answered. Here, we developed a
novel experimental framework where we combine the use of cytotoxic CD8+ T-cell
lines and ex vivo CD8+ T cells from HIV-1-infected individuals with functional assays of
LRA-inducible reactivation to delineate immune barriers to clear the reservoir. Our results
demonstrate the potential for early recognition and killing of reactivated cells by CD8+ T
cells. However, the potency of LRAs when crossing the barrier for antigen presentation in
target cells, together with the lack of expression of inhibitory receptors in CD8+ T cells,
are critical events to maximize the speed of recognition and the magnitude of the killing
of LRA-inducible provirus. Taken together, our findings highlight direct limitations in LRA
potency and CD8+ T cell functional status to succeed in the cure of HIV-1 infection.
Keywords: human immunodeficiency virus, HIV-1 reservoir, HIV-1 immunogen, shock and kill, CTL (Cytotoxic T
lymphocyte), inhibitory receptors
INTRODUCTION
The introduction of antiretroviral treatment (ART) has increased life expectancy and improved the
health of people living with HIV-1 infection. However, ART does not cure HIV-1 infection, and
treatment is needed for decades, thus raising the alarm about long-term health and sustainability of
treatment and care of HIV-1-infected individuals (1). The current limitations of ART highlight the
need for therapeutic strategies to eradicate HIV-1 from the body. A major obstacle to eradication is
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the establishment of the HIV-1 reservoir (2). Besides,
the reservoir is perpetuated through cellular homeostatic
proliferation and clonal expansion, even after years of effective
ART (3, 4).
One therapeutic approach, the so-called shock and kill
strategies, has been tested in several clinical trials and proposes
the use of latency-reversing agents (LRA) for the transcriptional
activation of HIV-1 (shock) and the clearance of reactivated
cells by immune responses (kill). Although several studies have
demonstrated reactivation of HIV-1 by LRA both in vitro
and in vivo (5–7), no measurable reduction in the HIV-1
reservoir has been found to date (8). Consequently, ensuring
the immune recognition of LRA-reactivated cells by effector
responses will be essential for eradication of the HIV-1 reservoir
(9, 10). Several studies have proposed CD8+ T cells as effector
cells for recognition and clearance of LRA-reactivated cells
(11) based on their ability to control the reservoir size in
natural controllers (12–14), their potent in vitro antiviral activity
(15, 16), and their role in controlling viral replication despite
ART (17). Although the frequency of HIV-1–specific CD8+
T cells decays with ART (18, 19), the cells retain effector
and cytotoxic properties that enable them to recognize and
kill HIV-1-infected cells (11, 17, 20, 21). However, functional
barriers to CD8+ T-cell antiviral activity upon treatment with
LRA can affect the success of shock and kill strategies. These
barriers may be associated with CD8+ T-cell dysfunction,
which is a consequence of LRA treatment itself, and with
the pro-inflammatory environment driven by HIV-1 infection.
Several studies suggest an immunosuppressive effect of LRA,
particularly histone deacetylase inhibitors (HDACi), on CD8+
T-cell antiviral activity (22, 23). Data remain controversial, and
while some studies suggest a time-dependent or direct effect
of HDACi on CD8+ T-cell function (24), others do not find
a measurable impact on ex vivo CD8+ T-cell function after
in vivo administration of HDACi (7). Moreover, the chronic
pro-inflammatory environment and the persistence of antigen
exposure affect the functional profile of HIV-1–specific CD8+ T-
cell responses (25, 26). This pro-inflammatory environment leads
to the reduction of cytotoxic potential and the upregulation of
inhibitory receptors, such as PD-1, LAG-3, and TIM-3 in CD8+
T cells associated with dysfunction and immune exhaustion in
HIV-1-infected individuals (27–30).
In this context, fundamental questions regarding the
limitations of LRA activity on target cells and CD8+ T-cell
sensing in response to HIV-1 reactivation remain unanswered.
In this study, we design a novel experimental framework where
we combine cytotoxic HIV-1 CD8+ T-cell lines (CTL) and
ex vivo CD8+ T cells from HIV-1-infected individuals with an
in vitro model of LRA-dependent HIV-1 reactivation. In this
framework, we evaluate the so-called window of opportunity
between latency reversal and killing of reactivated cells by
CD8+ T cells. We characterize HIV-1 protein expression upon
treatment with LRA and its association with antigen presentation
and delineate the kinetics of recognition and killing of HIV-1
reactivated cells by CD8+ T cells. We also analyze the functional
limitations of CD8+ T cells from HIV-1-infected individuals in
the elimination of reactivated cells. We observed a correlation
between LRA potency and the speed and magnitude of the
killing of reactivated cells by CD8+ T cells. Although we found
increased killing of reactivated cells by ex vivo CD8+ T cells
in response to LRA, the magnitude of the response was highly
variable across HIV-1-infected individuals and was associated
with a lack of expression of inhibitory receptors in CD8+ T cells.
Our data highlight several limitations in the efficacy of shock and
kill strategies and point to the need for a trade-off between LRA
potency and CD8+ T-cell functional status in HIV-1-infected
individuals if the reservoir is to be cleared.
RESULTS
LRA Allow HIV-1 Protein Expression and
HLA-Class I Antigen Presentation for
CD8+ T-Cell Recognition to Increase
Killing of Latently Infected Cells
First, we developed the “resting-like” or RELI-model to evaluate
HIV-1 reactivation by LRA (shock) simultaneously with the
elimination of reactivated cells by HIV-1-specific cytotoxic
CD8+ T-cell lines (CTL) (kill), as schematized in Figure 1A and
detailed in theMaterials andMethods section. Briefly, we infected
U937-HLA-B∗27:05 cells with the HIV-1NL43GFP reporter virus as
previously reported (31, 32). After 72 h of infection, we sorted the
GFP negative cells and cultured them for 4 days in the presence of
the protease inhibitor ritonavir (RTV). At this point, we obtained
a RELI population enriched in uninfected and non-productively
HIV-1-infected cells. RELI cells were then washed, treated with
the HIV-1 integrase inhibitor raltegravir (RAL) to avoid multiple
rounds of infection, and exposed to LRA shock for 48 h. We
also treated RELI cells with azidothymidine (AZT) to avoid the
formation of unintegrated episomal forms that may contribute
to the expression of viral proteins (data not shown) (33). LRA-
treated cells were then extensively washed to uncouple the LRA
effect from CD8+ T-cell function against reactivated cells (24),
and co-cultured with HLA-class I–matched HIV-1-specific CTLs
for 20 h (kill) (Figure 1A).
We measured HIV-1 reactivation in RELI cells in response
to LRA for 48 h including the HDACi panobinostat (PNBN),
romidepsin (RMD), trichostatin A (Tricho), and suberoylanilide
hydroxamic acid (SAHA). We also included combinations of
HDACi and bryostatin A (Bryo) to evaluate potential additive
effects between HDACi and protein kinase C agonists (PKCag)
as previously reported (34). Drug concentrations were selected
based on previous clinical or in vitro studies (7, 35–37) and
in the absence of direct cellular toxicity (Table S1). The use
of HIV-1NL43GFP enabled us to monitor viral reactivation by
flow cytometry using two markers the expression of p24 protein
(Figure 1B) and the expression of GFP encoded in frame with the
HIV-1 Nef protein, as previously reported (38, 39) (Figure 1C).
We observed a direct correlation between HIV-1 fold induction
measured according to p24 or GFP expression (p < 0.0001;
ρ = 0.94, Figure 1D). In this context, the expression of p24 was
consistently higher than that of GFP (p24 vs. GFP p < 0.005,
Wilcoxon matched-pairs signed-rank test) (Figure 1E), thus
indicating its greater sensitivity as a marker for viral antigen
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FIGURE 1 | The HIV-1 RELI “shock and kill”model. (A) Schematic representation of the HIV-1 RELI model for “shock and kill.” RELI cells were reactivated with LRA in
the presence of RAL before being extensively washed and cultured in the presence or absence of HLA-class I–matched CTL. After 20 h of co-culture, we
evaluatedHIV-1 reactivation (shock) and the killing of HIV-reactivated by CTL (kill). (B) Representative dot plots of intracellular p24 expression in live RELI cells under
untreated conditions (UT) compared with PMA/Ionomycin and SAHA and PNBN alone or combined with Bryo. (C) Representative dot plots of intracellular expression
of p24 and GFP from live RELI cells reactivated with LRA. The green square indicates GPF- positive cells, and the red square indicates p24-positive cells.
(D) Correlation between HIV-1 fold induction measured according to the expression of p24 or GFP in RELI cells after LRA treatment. The HIV-1 fold induction was
calculated as the ratio between % of p24- or GFP-expressing cells under LRA conditions and the % of p24- or GFP- expressing cells left untreated. The line indicates
the fit of the data to a linear regression. The Spearman correlation coefficient (ρ) and the two-tailed p-value are shown. The graph represents the mean ± SEM of three
independent experiments performed in replicates. (E) HIV-1 reactivation measured by the percentage of p24 positive cells or GFP-positive cells. The graph represents
the mean ± SEM of three independent experiments performed in replicates. (F) HIV-1 fold induction of RELI cells. The HIV-1-fold induction was calculated as the ratio
between the % of p24 expressing cells under LRA conditions and the % of p24-expressing cells in the left untreated. The data represents the mean ± SEM of five
independent experiments performed in replicates. The p–values were calculated using the one-sample t-test. Only significant values are shown in the figure
(*p < 0.05, **p < 0.005).
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FIGURE 2 | LRA treatment increased the magnitude of killing of HIV-1 reactivated cells by CD8+ T cells. (A) Representative dot plots showing the frequency of p24
cells from live HIV-1 reactivated cells in the absence (top) or in the presence of CTL1 for 20 h. (B) Frequency of p24 cells from HIV-1 reactivated cells inthe absence or
presence of CTLs (CTL1 and CTL2). The graph represents the mean ± SEM of three independent experiments performed in duplicate. (C) Fold-p24 expression
relative to SAHA-reactivated cells in the presence of HLA-matched CTLs treated with isotype control antibody IgG. SAHA-reactivated cells in the absence or presence
of HLA-matched CTLs (CTL1, CTL2), treated isotype control antibody IgG (IgG), and HLA-blocking antibody (W6/32), and in the presence of HLA-mismatched CTL3
(MM). The graph represents the mean ± SD of three experiments performed in duplicate. (D) Relative killing of RELI cells by untreated CTL1 and CTL2 and presence
of HDACi (including PNBN and SAHA) alone and combined with Bryo. Box and whisker plots included data from four independent experiments performed in
duplicate. The p-values were calculated using the Mann-Whitney test. Only significant values are shown in the figure (*p < 0.05).
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expression upon reactivation and supporting its application in
subsequent experiments. However, the use of GFP expression as
a marker of HIV-1 induction is particularly relevant given the
correlation between p24 and GFP expression for the screening
of large compound libraries and, thus, the increased cost-
effectiveness of the method.
As shown in Figure 1F, we compared HIV-1 reactivation
after LRA treatment with Tricho, PNBN, and SAHA alone or
combined with Bryo with untreated or DMSO controls. The
levels of HIV-1 reactivation ranged between a 2- and 4-fold viral
induction, with a significant increase for PNBN and SAHA alone
(p < 0.05) or combined with Bryo (p < 0.005). The additive
effects of combining HDACi/Bryo were modest or absent.
Next, we assessed whether LRA treatment enabled HIV-1
antigen presentation in the context of HLA-class I molecules for
their recognition and killing by HIV-1 cytotoxic CD8+ T-cell
lines (CTL). For this purpose, we used two CTLs, CTL1, and
CTL2, which recognized HLA-B∗27:05 restricted epitopes (Gag
KK10 and Pol KY9, respectively) as previously described (31).
Briefly, we exposed RELI cells to PNBN and SAHA alone or
combined with Bryo and co-cultured them with CTLs restricted
by HLA-B∗27:05. After 20 h of co-culture, we assessed killing by
measuring the frequency of p24-expressing cells in the absence
or presence of CTL1 (Figure 2A and Figure S1). As shown
in Figure 2B, we observed significantly increased killing by
CTL1 and CTL2 after LRA treatment (p < 0.0005, one-way
ANOVA). In fact, CTL1 and CTL2 were highly functional and
had similar 50% effective concentrations (EC50, −4.8, and −5.5,
respectively), despite differences in epitope specificity and a
higher response for CTL1 at low HIV-1 antigen concentrations
(Figure S2).
In addition, we added an anti-HLA-A/B/C (W6/32) antibody
or an HLA-mismatched (MM) CTL3 to demonstrate that, upon
viral reactivation, CTL killing was mediated through contacts
with class I HLA HIV-1 antigen complexes. The elimination of
reactivated cells was significantly abolished both by means of the
W6/32 antibody and by impeding the recognition of the HLA-
class I peptide complexes with an HLA-MM co-culture (p< 0.05,
one-way ANOVA) (Figure 2C). Thus, the compiled analysis of
all LRA tested showed a significant increase in the magnitude of
killing of cells latently infected by HIV-1 after LRA treatment in
both CTL (p < 0.05, Figure 2D). However, we did not observe
any additional benefit in the frequency of reactivated cell killing
through the combination of HDACi with Bryo (Figure 2D).
These data confirm that inducible reactivation of HIV-1 by
LRA enables antigen presentation in the context of HLA-class I
molecules to increase killing of latently infected cells by CTL.
LRA Potency Modulates the Speed of
HIV-1 Antigen Recognition and the
Magnitude of the Killing of Reactivated
Cells by CD8+ T Cells
It is essential to investigate the kinetics of recognition and
killing of LRA-reactivated cells and to establish a window
of opportunity between shock and kill by CD8+ T cells
for therapeutic optimization. By using the RELI model, we
monitored the kinetics of recognition and elimination of HIV-
1 reactivated cells by CTLs at 3, 6, and 20 h post co-culture.
We measured changes in the frequency of p24-positive cells
from time 0 by flow cytometry at 3, 6, and 20 h after co-
culture of untreated and LRA-treated RELI cells with CTLs
(Figure 3A). We observed a reduction in the frequency of p24-
expressing cells over time in culture with CTLs (Figure 3B). HIV-
1 reactivated cells were eliminated rapidly after 3 h of co-culture
in SAHA, PNBN, SAHA/Bryo, and PNBN/Bryo conditions
compared with untreated cells for both CTLs (untreated vs.
HDAC ± Bryo; p < 0.0001) (Figure 3C). These differences were
sustained at 6 h after co-culture (untreated vs. HDAC ± Bryo;
p < 0.0005) and 20 h after co-culture (untreated vs. HDAC ±
Bryo; p < 0.005) (Figures 3D,E). These data indicate a general
increase in the speed of recognition and killing of reactivated cells
by CTLs starting at 3 h in the presence of PNBN, PNBN/Bryo,
SAHA, and SAHA/Bryo, although our results do not reveal a
hierarchy for LRAs. The data suggest a prolonged effect over
the first 6 h by PNBN/Bryo, SAHA, and SAHA/Bryo compared
with untreated cells (Figures 3D,E) (untreated vs. PNBN/Bryo;
p < 0.05, untreated vs. SAHA, p < 0.005; and untreated vs.
SAHA/Bryo; p < 0.005). By contrast, the use of Bryo alone
did not significantly increase the speed or magnitude of killing
compared with untreated condition at 3, 6, or 20 h of co-culture
(Figures 3C–E). Although we observed a marginal augment in
the killing at early time points, suggesting an indirect effect of
Bryo in CTL activation despite extensive washout of the drug as
previously reported (24).
Interestingly, as shown in Figure 3F, we found a direct
correlation between the magnitude of CTL killing and the levels
of HIV-1 inducible reactivation by LRA at early time points (3 h
p < 0.0005, ρ = 0.74; 6 h p < 0.005, ρ = 0.68), thus indicating
that the potency of the LRA for HIV-1 antigen expression dictates
the speed of CTL recognition. Based on these data, we propose
a threshold of >2-fold HIV-1 induction upon LRA treatment
to allow antigen presentation and engage rapid recognition and
killing of HIV-1 reactivated cells by CTL.
Besides, we investigated whether HIV-1 killing by CTL can be
monitored by changes in cytokine expression and degranulation
upon antigen recognition using CTL as biosensors (40), we
measured CD107a/MIP1β and IFNγ expression (Figure 3G, dot
plots). Despite the increase of HIV-1 expression by LRAs, the use
of SAHA or PNBN did not alter the kinetics of CD107a/MIP1β or
IFNγ expression in the tested CTLs, as compared with untreated
conditions. By contrast, Bryo indirect effects increased both
CD107a/MIP1β and IFNγ secretion by CTLs at early time points
(Figure 3H). We also found different profiles for CD107a/MIP1β
and IFNγ expression over time, with increasing frequencies for
CD107a/MIP1β and decreasing frequencies for IFNγ secretion.
Thus, the kinetics of cytokine expression by CTLs did not mirror
changes associated with HIV-1 inducible reactivation or killing.
Overall, these data indicate a direct relationship between the
potency of inducible reactivation of HIV-1 by LRA and the speed
of recognition and killing of reactivated cells by CD8+ T cells.
Therefore, the potency of LRA to cross the threshold of HIV-
1 antigen presentation in reactivated cells is a crucial event to
shortening the window of opportunity for antigen recognition,
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FIGURE 3 | Kinetics of killing in response to HIV-1 reactivation by CTL. (A) Representative dot plots showing the percentages of intracellular p24 from HIV-1 RELI
cells. The top line indicate the level of HIV-1 reactivation of RELI cells at baseline (0 h) in untreated and LRA-treated conditions and 3, 6, and 20 h after co-culture with
CTL1 (B) Kinetics of elimination of HIV-1 reactivated by CTL. The graph shows the mean ± SEM of two independent experiments for CTL1. (C) Kinetics of killing of
HIV-1 reactivated cells by CTLs at 3 h; (D) at 6 h; (E), and at 20 h after co-culture. Values in graphs C to E correspond to the mean ± SEM of three independent
experiments for CTL1 and three independent experiments for CTL2 in replicates. The p-values were calculated using the unpaired t-test for comparisons between
untreated cells and cells treated with HDACi (top line) and one-way ANOVA for multiple comparisons (asterisks above the bars). Only significant p-values are
represented in the figure (*p < 0.05, **p < 0.005, ***p < 0.0005, ****p < 0.00005). (F) Correlation between HIV-1 fold induction and frequency of killing mediated by
CTLs. The line indicates the fit of the data to a linear regression. The Spearman correlation coefficient (ρ) and the two-tailed p-value are indicated. The graph
represents the frequency of killing from three independent experiments for CTL1 in replicates and three independent experiments for CTL2 in replicates.
(G) Representative dot plots showing percentages of CD107a/MIP1β from CTL1 after co-culture with HIV-1 reactivated RELI cells. (H) Kinetics of CD107a/MIP1β and
IFNγ secretion from CTLs after co-culture with HIV-1 reactivated RELI cells. The graphs show the mean ± SEM of two independent experiments for CTL1 and two
independent experiments for CTL2 in replicates.
Frontiers in Immunology | www.frontiersin.org 6 January 2019 | Volume 9 | Article 3162
Ruiz et al. Barriers to HIV-1 Shock and Kill
thus maximizing CD8+ T-cell sensing for elimination of HIV-1
reactivated cells.
Inter-individual Divergences in ex vivo
CD8+ T-Cell Recognition and Killing of
LRA-Reactivated Cells
Although the use of CTL supports rapid recognition of HIV-1
reactivated cells based on LRA potency, these CTL are highly
functional and sensitive to HIV-1 antigen presentation and may
not fully recapitulate the diversity of HIV-1–specific CD8+ T
cells in infected individuals.
To delineate the kinetics of recognition and killing of LRA-
reactivated cells by CD8+ T cells, we initially co-cultured
SAHA-treated cells with ex vivo CD8+ T cells obtained from
three of the eight HIV-1-infected individuals tested (participants
characteristics in Table 1). As shown in Figure 4A, we observed
variation in the kinetics of recognition and killing of reactivated
FIGURE 4 | Killing of HIV-1 reactivated cells by ex vivo CD8+ T cells. (A) Percentage of killing of untreated or SAHA-treated HIV-1 RELI cells at 3 and 20 h by ex vivo
CD8+ T cells from HIV-1-infected individuals (n = 3). (B) Percentage of killing of untreated or SAHA-treated HIV-1 RELI cells by ex vivo CD8+ T cells at 20 h (n = 7).
(C) Paired comparison of the percentage of killing of untreated or SAHA-treated HIV-1 cells by ex vivo CD8+ T cells shown in (B). The graph represents the
percentage of the killing of RELI cells. The p-values were calculated using the paired t-test. (D) Percentage of killing of untreated or SAHA-treated RELI cells by ex vivo
CD8+ T cells from PT3. Conditions with a 1X SAHA and 2X SAHA and co-cultures at an E:T ratio of 3:1 in 1X SAHA conditions are shown. (E) Percentage of CD8+ T
cells in contact with untreated or SAHA-treated HIV-1 RELI cells in the absence or presence of a W6/32 antibody after 20 h of co-culture. The p-values were
calculated using the paired t-test. (F) Percentage of CD107a/MIP1β and IFNγ secretion by CD8+ T cells after 20 h in contact or not (CT/non-CT) with
SAHA-reactivated cells. The p–values were calculated using the paired t-test. Only significant values (*p < 0.05, **p < 0.005 and ***p < 0.0005) are shown.
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TABLE 1 | Characteristics of study participants.
Participant ID Age at sample Gender, Ethnicity ART regimen HLA-B serotype VL (copies/ml)
PT1 34 M, CAU TDF/FTC/RAL B*27:05 <40
PT2 43 F, CAU Naïve B*27:02 <40
PT3 36 M, CAU ABC/3TC/DTG B*27:05 <40
PT4 38 M, CAU TDF/FTC/RAL B*27:05 <40
PT5 36 M, CAU Naïve B*27:05 44000
PT6 40 M, CAU TDF/FTC/ELV/COB B*27:05 <40
PT7 37 F, CAU Naïve B*27:05 982
MM 47 M, CAU AZT/DDC Non-B*27 <40
VL, viral load; MM, mismatch; TDF, tenofovir; FTC, emtricitabine; RAL, raltegravir; ABC, abacavir; 3TC, lamivudine; DTG; dolutegravir; ELV, elvitegravir; COB, cobicistat; AZT, zidovudine;
DDC, zalcitabine.
cells by ex vivo CD8+ T cells. While we observed killing in
response to SAHA at 3 h for PT1, we did not observe elimination
of reactivated cells for PT2; in addition, elimination of reactivated
cells was only observed after 20 h of co-culture for PT3. These
divergences suggest functional differences between CD8+ T cells
from HIV-1-infected individual associated a particular profile of
recognition and killing of LRA-reactivated cells (41).
Next, we extended our initial analyses to an additional group
of HIV-1-infected individuals (Table 1). As in the previous
experiments, we found high inter-individual variability in the
killing capacity of HIV-1-reactivated cells by CD8+ T cells
ranging from 2% (PT2 and PT7) to 70% (PT4 and PT5)
(Figure 4B). The killing observed was specific for CD8+ T-
cell recognition in the context of HLA-class I presentation, as
supported by the lack of killing observed by mismatch CD8+
T cells (MM). Despite this biological divergence, we observed a
significant increase in the killing of SAHA-treated cells by CD8+
T cells (p < 0.05, Figure 4C). Moreover, we were able to enhance
themagnitude of CD8+ T-cell killing ex vivo, either by increasing
the concentration of SAHA 2-fold or the effector-to-target ratio
3 times (Figure 4D). These results demonstrate the possibility of
modulating and improving the efficacy of CD8+ T-cell killing in
response to HIV-1 inducible expression by higher LRA dosage or
higher frequency of effector cells. We also carried out a detailed
study of cell-to-cell interactions in our co-culture system. We
observed an increase in the number of CD8+ T-cell contacts
with target cells upon reactivation of SAHA (p < 0.005). These
contacts were specifically blocked by the addition of an anti-
HLA-A/B/C antibody (p< 0.05) (Figure 4E), thus demonstrating
the dependency of cell-to-cell contact on the interactions between
TCR and HLA-class I/peptide complexes after LRA treatment.
In addition, CD8+ T cells that established contact were highly
functional, asmeasured by the levels of CD107a/MIP1β and IFNγ
when compared with CD8+ T cells lacking contacts with target
cells (p < 0.0001) (Figure 4F).
These findings support an overall increase in the killing of
HIV-1-infected cells by CD8+ T cells upon LRA induction of
viral reactivation despite inter-individual divergences. Moreover,
our data point to the opportunity to optimize the immune
clearance of HIV-1 reactivated target cells by CD8+ T cells by
increasing the LRA dosage and the frequency of effector CD8+ T
cells.
Expression Profiles of Inhibitory Receptors
in HIV-1–Specific CD8+ T Cells Modulates
the Killing of HIV-1 Reactivated Cells
Inter-individual differences in functional ability to recognize
and eliminate HIV-1-infected cells ex vivo by CD8+ T cells
could be the result of differences in time to initiation of
ART (42), in the persistence of antigen exposure and in the
chronic pro-inflammatory environment despite ART (30). The
pro-inflammatory environment and the long-term exposure
to antigen lead to dysfunctional HIV-1–specific CD8+ T-cell
responses and eventually to immune exhaustion.
To delineate the determinants of CD8+ T-cell dysfunction
in response to LRA-reactivated cells, we cultured CTLs with
HIV-1 cognate peptide for 9 weeks with weekly rounds of
peptide re-stimulation to simulate in vitro long-term antigen
exposure (Figure 5A). At weeks 0, 5, 7, and 9 we performed
an immune phenotype of inhibitory receptors (PD-1, LAG3,
and TIM-3) and the immune-metabolic marker CD39. All these
markers have been previously associated with the exhaustion
of HIV-1–specific CD8+ T-cell responses (28, 43). As shown
in Figure 5B, we found a significant reduction in the killing
of LRA-reactivated cells by CTL after 9 weeks of continuous
antigen exposure (p < 0.005). Despite the overall reduction in
the killing by CTL after 9 weeks, we did observe an increase
in killing between untreated and SAHA conditions (35–58%)
(Figure 5B).
We also monitored phenotypic changes in CTL and
found a contraction in the frequency of subpopulations
without expression or expressing a single inhibitory receptor
concomitant with the expansion of cells co-expressing three
or four inhibitory receptors over time (Figure 5C, pie charts).
This phenotype of expansion/contraction was coincident
between CTL1 and CTL2, which vary in HIV-1 antigen
specificity. However, the specific combinations of inhibitory
receptors diverge between CTL lines and time, thus highlighting
the diversity of T-cell inhibitory pathways. Also, CD39+
subpopulations appeared after 5 weeks in cells already expressing
two or more inhibitory receptors (Figure 5C, arcs). These
data suggest the presence of terminally exhausted CD8+ T
cells identified by CD39 expression, as previously described
(43).
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FIGURE 5 | CD8+ T-cell dysfunction impairs clearance of HIV-1 reactivated cells associated with an increase in the co-expression of inhibitory receptors.
(A) Schematic representation of the in vitro exhaustion process, where CTL were exposed to HIV-1 cognate peptide over a period of 9 weeks. (B) Percentage of killing
of HIV-1 reactivated cells by CTL after antigen stimulation at week 0 and at 9 weeks. The graph includes one representative experiment. The p-value was calculated
using the paired t-test. Statistical significance is shown in the figure (*p < 0.05). (C) Pie charts representing the fraction of cells expressing different combinations of
PD-1, LAG3, TIM-3, and CD39 at weeks 0, 5, 7, and 9 after antigen stimulation.
Based on these data and the biological diversity found in
the recognition and killing of LRA-reactivated cells by ex vivo
CD8+ T cells, we measured HIV-1–specific CD8+ T-cell
function in response to a pool of Gag overlapping peptides. We
monitored expression of CD107a, IFNγ, and MIP1β cytokines
and of PD-1, LAG3, TIM-3, and CD39 by multiparametric flow
cytometry. As shown in Figure 6A, we observed variation in the
profile of cytokine production among individuals in response to
HIV-1. Meanwhile, the functional response to SEB control
stimuli was very homogeneous, as expected. Furthermore,
we did not find a correlation between the frequency of
polyfunctional cells among the HIV-1–specific CD8+ T cells
and the killing in response to LRA-reactivated cells, as it has
previously been associated with spontaneous control of HIV-1
replication (44, 45). Importantly, individuals harboring HIV-1–
specific CD8+ T cells lacking expression of inhibitory receptors
retained the highest suppressive capacity against HIV-1 LRA-
reactivated cells (Figure 6B). Thus, PT5 responded to LRA
treatment with a 68% in vitro suppressive capacity and 63%
of HIV-specific CD8+ T cells lacking inhibitory receptors.
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FIGURE 6 | Expression profiles of cytokines and inhibitory receptors in HIV-1–specific CD8+ T cells. (A) Functional profiles of HIV-1–specific CD8+ T cells. Pie charts
represent functional profiles associated with the secretion of IFNγ, CD107a, and IL-2 in relation with IFNγ+ single, double (IFNγ+CD107a+IL-2-,IFNγ+CD107a-
IL-2+), and triple positive cells (IFNγ+CD107a+IL−2+). Data from four HIV-1-infected individuals following 6 h of stimulation with SEB or a pool of HIV-1 Gag
peptides is shown. (B) Profiles of inhibitory receptor (iR) expression in HIV-1–specific CD8+ T cells from infected individuals taken from IFNγ positive cells. For (A,B)
the pie slices represent the frequency of cells with expression of one or more markers, and the pie arcs represent the specific markers expressed. The gray gradient
below indicates the magnitude of killing of HIV-1 reactivated cells by four HIV-1-infected individuals. (C) Correlation of the frequency of HIV-1–specific CD8+T cells
lacking iR expression and the magnitude of SAHA-reactivated cell killing. The line indicates the fit of the data to a linear regression. The Spearman correlation
coefficient (r) and the two-tailed p-value are indicated.
Participants PT3, PT1, and PT7 with 36, 35, and 24% of
HIV-1–specific CD8+ T cells lacking inhibitory receptors had
suppressive capacities achieving 19, 10, and 2% of killing
of SAHA reactivated cells. Although limited by sample size,
our data delineate a correlation between the percentages of
HIV-1–specific CD8+ T cells lacking inhibitory receptors
and their immune responsiveness to killing LRA treatment
(p < 0.005, Figure 6C).
According to these data, changes in the profile of inhibitory
receptors in HIV-1-specific CTL and primary CD8+ T cells
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modulate their antiviral potency. Therefore, the levels of
inhibitory receptor co-expression in CD8+ T cells can limit the
magnitude of the killing of HIV-1-reactivated cells.
DISCUSSION
Clinical use of LRA revealed detectable perturbations in the
HIV-1 reservoir with no measurable impact on reservoir size
(5–8). Therefore, the potential of shock and kill strategies
to purge HIV-1 reservoirs should be carefully evaluated to
delineate current therapeutic limitations. On the one hand,
LRA should be able to induce HIV-1 latency reversal for
recognition by immune effector cells. On the other, the functional
characteristics of CD8+ T cells should ensure the effective
clearance of reactivated cells. Here, we report the barriers
that account for the immune recognition of HIV-1 latently
infected by CD8+ T cells in the context of shock and kill
cure strategies. Our data demonstrate the potency of LRA for
speeding up the recognition of reactivated cells and CD8+
T-cell dysfunction associated with the expression of inhibitory
receptors as limitations to ensure the killing of HIV-1 reactivated
cells. Thus, we characterize the level of HIV-1 protein expression
upon treatment with LRA as a mechanism that is essential for
rapid and potent killing of reactivated cells by CD8+ T cells.
Moreover, our findings suggest high inter-individual variation
in CD8+ T-cell responsiveness to HIV-1 reactivation, where the
expression of inhibitory receptors modulates the magnitude of
killing.
As shown by previous reports, we found how reactivation of
latently infected cells by LRA enables HIV-1 antigen presentation
for recognition and killing by CD8+ T cells (7, 46). Our data
are consistent with those from previous studies and suggest
that once LRA induced HIV-1 antigen production, there was
no interference in antigen presentation in the context of HLA-
class I molecules for recognition by CD8+ T cells (22). In
addition, we were able to characterize in detail the characteristics
of the so-called window of opportunity between reactivation
and killing for CD8+ T cells. In our experimental framework,
the killing of reactivated cells can happen as early as 3 h after
co-culture, under conditions where LRA treatment achieves
the highest reactivation level. The correlation between LRA
potency measure as HIV-1-fold induction, and the speed of
recognition by CD8+ T cells uncover the presence of a threshold
of antigen production after administration of LRA for killing.
Although our experimental data propose a threshold above a
2-fold induction of HIV-1 reactivation for CD8+ T-cell killing,
we need to remember that the data were obtained in the
context of two particular CTL. Our results constitute a proof
of principle on the need for potent LRAs to ensure the rapid
recognition of HIV-1 reactivated cells for effective shock and
kill strategies, even in the context of fully functional CD8+
T-cell responses. However, we cannot extrapolate the current
findings as this theoretical threshold may vary across HIV-1-
infected individuals with differences in TCR affinities (31, 47).
It is necessary to perform further experiments that evaluate
diversity in TCR affinities between CD8+ T-cell clonotypes
in HIV-1-infected individuals in the context of LRA in order
to ensure accurate delineation of the early reactivation events
and broad immune recognition of LRA-reactivated cells. The
consistency of our data across the CTLs used may indicate
that clearance of reactivated cells is independent of CTL
antigen specificity when an adequate threshold of reactivation is
reached.
Furthermore, we did not find differences in the levels of
cytokines secreted by CTL between untreated and HDACi-
treated conditions, which may constrain their use as biosensors
of HIV-1 reactivation events, as previously suggested (40). As
mentioned, the use of highly sensitive CTL in our experiments
may limit their capacity to detect small differences in the
number of antigens presented between the conditions tested.
Thus, we propose to explore additional markers of CD8+ T-
cell activation to validate their use as biosensors of HIV-1
reactivation. We also detected a significant increase in cytokine
secretion and killing by CTL under Bryo conditions in the
absence of HIV-1 reactivation (22, 24). Such a pre-activation
status driven by residual Bryo despite extensive washout, or by
the direct effect of Bryo on target cells did not show a measurable
benefit concerning faster or better killing when compared with
HDACi alone. These data alert to the potential effect of using
Bryo, which leads to undesirable and non-specific CD8+ T-cell
activation and cytokine release, as suggested in other studies
(23, 24).
Together with LRA potency, CD8+ T-cell functional status
is essential to guaranty the efficacy of shock and kill strategies
to clear the HIV-1 reservoir. Our data indicate biological
diversity across ex vivo CD8+ T cells from HIV-1-infected
individuals in response to LRA-reactivated cells. In our
experimental framework, we can exclude some of the barriers
for CD8+ T-cell function, including viral escape (20), anatomical
compartmentalization (48), and lack of viral protein translation
(21). Therefore, the differences observed here are mainly due
to functional differences between CD8+ T cells from HIV-1-
infected individuals. Although we demonstrate an increase in the
killing of reactivated cells by ex vivoCD8+ T cells after treatment
with SAHA, we found differences in the kinetics and the total
magnitude of killing between individuals. These differences in
response to LRA treatment reflect the heterogeneity of the HIV-
1–specific CD8+ T cell responses, even in the context of the
HLA-B∗27 allele expressed in our target cells, which has been
associated with strong antiviral responses and elite control of
HIV-1 (14).
Multiple factors account for the functional diversity of HIV-
1–specific-CD8+ T-cell responses irrespective of the clinical
stage of HIV-1, including the low frequency of HIV-1–specific
CD8+ T cells upon antigen clearance by long-term ART
and continuous immune CD8+ T-cell activation despite ART
(18, 19). Moreover, HIV-1–specific CD8+ T-cell dysfunction is
associated with a high level of expression of inhibitory receptors
including PD-1, TIM-3, LAG-3, and TIGIT (26, 27, 29). These
markers have been associated with CD8+ T-cell dysfunction
and terminal exhaustion in chronic infections (25, 30). Our in
vitro data demonstrate that upon continuous exposure to HIV-
1 antigens, there is a contraction of subpopulations lacking
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inhibitory receptors. This is concomitant with the expansion
of CTL subpopulations co-expressing at least three inhibitory
receptors, including PD-1, LAG3, TIM-3, and the metabolic
marker CD39 (43). In our experimental setting, the expansion
of CTL co-expressing inhibitory receptors over time diminished
the magnitude of the killing of LRA-reactivated cells. However,
our in vitro model does not account for the pro-inflammatory
environment of HIV-1 infection. Further studies including the
use of pro-inflammatory cytokines and characterization of the
expression of inhibitory receptors in tetramer-sorted HIV-1–
specific cells expose to HIV-1 peptides will help to clarify whether
our findings can be extended toHIV-1–specific circulating CD8+
T cells.
Despite the limitations mentioned, our findings were
consistent with the direct use of ex vivo CD8+ T cells, where
the frequency of HIV-1–specific CD8+ T cells lacking inhibitory
receptors directly correlated with the magnitude of killing of
LRA-reactivated cells. This is the first study to our knowledge
that suggest an inter-dependency between CD8+ T-cell function
and the expression patterns of inhibitory receptors in response to
HIV-1 reactivation (28).
The identification of novel inhibitory receptors as markers
of HIV-1–specific CD8+ T-cell dysfunction has increased in
recent years. The interest has risen due the unprecedented
success of clinical trials targeting inhibitory receptors in cancer
regression (49, 50). Consequently, additional efforts are needed
to clarify the impact of inhibitory receptor blockade in HIV-
1-infected individuals. Immunotherapy based on blockage of
inhibitory receptors has proven effective in various types of
cancer. The use of PD-1 inhibitors have demonstrated to be
safe and effective in HIV-infected individuals with lung cancer
(51). Moreover, the use of an anti-PD-L1 in HIV-1-infected
individuals has already been evaluated in a Phase I clinical
trial (52), in which anti-PD-L1 had a limited effect on the
recovery of HIV-1–specific CD8+ T-cell responses (2 out of
6 patients). Consequently, the delineation of the functional
characteristics of HIV-1–specific CD8+ T cells behind successful
shock and kill strategies will play a key role in the assessment
of treatment efficacy. The efforts to define these traits should
accompany the development of ultrasensitive technologies for
the monitoring of small perturbations in the size of the
HIV-1 reservoir in response to low fractions of reactivated
cells killed by CD8+ T cells in blood or tissues. These
technologies will be essential to guide the outcome of curative
strategies.
In summary, our study suggests the need for a strong flush
of latent virus to speed up recognition of HIV-1 reactivated
cells and an adequate functional capacity of HIV-1–specific
CD8+ T cells to maximize elimination of LRA-reactivated cells.
An adequate trade-off between shock and kill is essential to
ensure the success of potential curative strategies. The immune
characterization of HIV-1–specific CD8+ T-cell responses,
including patterns of inhibitory receptors associated with the
killing of reactivated cells, will allow the design of novel immune-
monitoring and immuno based therapeutics to ensure effective
antiviral responses before latency reversal in HIV-1-infected
individuals.
MATERIALS AND METHODS
Virus and Cell Lines
The virus NL43GFP was generated by co-transfection of
p83–2 and p83–10eGFP plasmids in MT4 cells (NIH AIDS
Reagent program, USA) based on electroporation, as previously
described (38, 39). The cell-free supernatant was concentrated
by spinoculation at 24,000 rpm at 4◦C for 90min, and stored
at −80◦C. The 50% tissue culture infective dose (TCID50) was
determined on TZM-bl cells (NIH AIDS Reagent program, USA)
as described in Kloverpris et al. (31). The HIV-1-permissive
U937 cell line transfected with the HLA-B∗27:05 gene (kindly
provided by Paul Bowness, UK) (53) was cultured in RPMImedia
supplemented with 10% fetal calf serum (FCS) (HyClone), 2mM
L-glutamine, 100 U/ml penicillin, 100µg/ml streptomycin, and
0.5 mg/ml geneticin (Invitrogen, Life Technologies). The HIV-1
cytotoxic CD8+ T-cell lines (CTL) used were restricted by HLA-
B∗27:05. The CTL1 was specific for the KK10 epitope in Gag
and CTL2 for the KY9 epitope in Pol. In addition, CTL3 was
restricted by HLA-B∗57:01 and specific for the KF11 epitope in
Gag (31, 53).
The HIV-1 Shock and Kill RELI Model
The U937 HLA-B∗27:05 permissive cell line was infected with
NL43GFP by magnetofection at a dose equivalent to a nominal
multiplicity of infection (MOI) of 0.1, as previously reported
(31, 32). After magnetofection, cells were washed twice with
1X PBS and cultured in R10 + geneticin (0.5 mg/ml). At
day three post-infection, the GFP-negative population, which
included the non-productively infected cells enriched in HIV-1
integrated provirus, was sorted with a FACS Aria II Cell Sorter
(BD Biosciences) and cultured in the presence of 1µM of RTV
(Sigma, Spain). After 4 days, we obtained a culture enriched in
“resting-like” cells (RELI). Themean levels of cell-associated total
HIV-1 DNA in RELI-lysates was 5.1–log ± 0.19 log10 copies/10
6
RELI as measured by droplet digital PCR previously described in
Martínez-Bonet et al. (54). RELI cells were treated with LRA in
the presence of RAL at 100 nM (Sigma, Spain) to monitor HIV-
1 reactivation or “shock.” The LRA panel included the HDACi:
panobinostat (PNBN) at 30 nM (SelleckChem, USA), trichostatin
A (Tricho) at 250 nM (Sigma, Spain), SAHA (suberoyl aniline
hydroxamic acid) at 1µM (SelleckChem, Spain), and romidepsin
(RMD) at 40 nM (SelleckChem, Spain), and the PKC agonist
bryostatin A (Bryo) at 10 nM (Sigma, Spain). RELI cells were
treated for 48 h with LRA except for RMD-treated cultures,
where the drug was washed-off after 4 h to avoid cellular
toxicity.
To monitor the “shock” or HIV-1-fold induction at 48 h after
treatment with LRA, the RELI cells were harvested and stained
with a Live/Dead probe (APC-Cy7, Invitrogen). After washing,
cells were fixed and permeabilized with the Fix&Perm kit (A
and B solutions, Thermo Fisher Scientific) for intracellular HIV-
1 p24 (PE, clone KC57-RD1, Beckmann Coulter). Cells were
acquired on an LSR II flow cytometer (Beckmann Coulter),
and data were analyzed using FlowJoV (Tree Star Inc.). The
HIV-1-fold induction was calculated based on the following
equation: % of p24+ or GFP+ in CD4+ under LRA conditions/%
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of p24+ or GFP+ under untreated conditions. To proceed
with the co-cultures to monitor the “killing” of reactivated
cells by CD8+ T cells the RELI cells were extensively washed
with 1X PBS and left in R10 media plus RAL. Thus, we
cultured LRA-reactivated RELI cells in the absence or presence
of HIV-1-specific CTLs or B∗27-HLA-matched ex vivo CD8+ T
cells obtained from HIV-1-infected individuals. Cells were co-
cultured to a 1:1 effector: target ratio for 20 h. After 20 h of
co-culture, we simultaneously measured by flow cytometry the
“shock” by intracellular p24, and the “kill” by the reduction of
p24-positive RELI cells in the absence or presence of effector
cells. We also assessed LRA-related toxicity both in uninfected
U937 cells and in the RELI model by measuring cellular viability
using flow cytometry and staining with a Live/Dead probe
(APC-Cy7, Invitrogen) at the end of the co-culture with RELI
and CTL.
CD8+ T-Cell Killing and Activation
We performed CD8+ T-cell killing experiments of LRA-
reactivated cells with CTL or ex vivo CD8+ T cells at 20 h after
culture. We also monitored the kinetics of CD8+ T-cell killing
of LRA-reactivated cells with CTL or ex vivo CD8+ T cells
after 3, 6, and 20 h after co-culture. We monitored CTL and
CD8+ T-cell activation by intracellular expression of CD107a,
MIP-1β, and IFNγ. For analysis of HLA-class I restriction, the
W6/32 antibody (BioLegend, Spain) or the isotype control LEAF
purified IgG2aÎ (BioLegend) was added to the co-culture at
10µg/ml. For analysis of CD8+ T-cells in contact with RELI
cells, we analyzed the percentage of doublets gated cells that
expressed the CD8+ surface marker in the target cells gate.
For analysis of early CD107a secretion, the antibody CD107a
(PerCP-Cy5.5, BD Biosciences) was added to the co-culture.
For the immune-phenotype, samples were collected and washed
twice with 1X PBS and incubated for 3 h in the presence of
the protein transport inhibitor Golgiplug (Brefeldin A solution,
BD Biosciences, Spain) and Golgistop (Monensin solution, BD
Biosciences, Spain). Cells were then harvested, stained with a
Live/Dead probe (APC-Cy7, Invitrogen). Next, cells were washed
and stained to identify the surface marker CD8 (Pacific blue,
clone RPA-T8, BD Biosciences). After washing, cells were fixed
and permeabilized with the Fix&Perm kit (A and B solutions,
Thermo Fisher Scientific) for intracellular cytokine staining of
MIP1β (FITC, clone 24,006, R&D Systems), IFNγ (PE-Cy7,
clone 4S.B3, BD Biosciences), and HIV-1 p24 (PE, clone KC57-
RD1, Beckmann Coulter). Cells were acquired on an LSR II
flow cytometer (Beckmann Coulter). Data were analyzed with
FlowJoV (Tree Star Inc.). The killing of reactivated HIV-1 cells
by CTL/CD8+ was calculated based on the following equation:
100—[(% p24+ in CD4+ co-cultured with CD8+/% p24+ in
CD4+ in the absence of CD8+)× 100].
In vitro CTL Exhaustion Experiments
To characterize potential markers associated with CTL
dysfunction in response to LRA-reactivated cells, we exposed
CTL1 and CTL2 to cognate HIV-1 antigen over nine weeks.
To do so, we stimulated CTL with a 1:1 mixture of irradiated
autologous B-cell lines (BCLs) pulsed with cognate HIV peptide
(10µg/ml) and irradiated PBMCs from three healthy HIV-
seronegative donors weekly. We used flow cytometry to evaluate
variations in the expression of the inhibitory receptors PD-1,
TIM-3, LAG-3, and the immune-metabolic marker CD39.
Briefly, cells were taken from the culture at weeks 0, 5, 7, and
9 and stained with a Live/Dead probe (APC-Cy7, Invitrogen)
and surface markers CD3 (Alexa700, BD Biosciences), CD4
(APC-Cy7, BD Biosciences), CD8 (V500, BD Biosciences), PD-1
(BV421, BD Biosciences), TIM-3 (Alexa 647, BD Biosciences),
LAG-3 (PE, BD Biosciences), and CD39 (FITC, BD Biosciences)
and incubated at room temperature for 25min. Samples were
washed twice with 1X PBS, fixed in 1% formaldehyde, and
acquired on an LSR Fortessa. Data were analyzed with FlowJoV
(Tree Star Inc.). Patterns of co-expression of PD-1, LAG-3,
TIM-3, and CD39 were analyzed using Pestle and SPICE v5
software (55).
Immunophenotype of HIV-1–Specific CD8+
T-Cell Responses
The PBMCs from HIV-1-infected individuals were stimulated
with HIV-1 Gag peptide pool (2 µg/peptide/ml, EzBiolab), or
the positive control SEB (enterotoxin B from Staphylococcus
aureus, Sigma, Ref. S4881) or no stimuli in the presence of
CD28/49d co-stimulatory molecules (1 µl/ml, BD Biosciences),
Golgistop solution (Monensin A, BD Biosciences, Spain), and
anti-human CD107a (PE-Cy5, BD Biosciences) for 6 h at 37◦C
in a 5% CO2 incubator and overnight at 4
◦C. Stimulation cells
were then washed with 1X PBS and stained for 25min with the
Live/Dead probe (APC-Cy7, Invitrogen). Next, cells were washed
with 1X PBS and surface stained for 25min with CD3 (A700,
BD Biosciences), CD4 (APC-Cy7, BD Biosciences), CD8 (V500,
BD Biosciences), PD-1 (BV421, BD Biosciences), LAG3 (PE, BD
Biosciences), TIM-3 (A647, BD Biosciences), and CD39 (FITC,
BD Biosciences). Subsequently, cells were washed twice in 1X
PBS and fixed and permeabilized with the Fix&Perm kit (A and
B solutions, Thermo Fisher Scientific) for intracellular cytokine
staining of IFNγ (BV711, BD Biosciences) and IL-2 (BV650,
BD Biosciences). After 20min at room temperature in the dark,
stained samples were washed twice with 1X PBS, resuspended in
1% formaldehyde and acquired on an LSR Fortessa. Data were
analyzed with FlowJoV (Tree Star Inc.). Patterns of simultaneous
expression of IFNγ, CD107a, and IL-2, or combinations of PD-1,
LAG-3, TIM-3, and CD39 were analyzed using Pestle and SPICE
v5 software (55).
Statistics
Statistical analyses were performed using Prism v4 (GraphPad
Software, Inc.). Reported p-values were calculated using the
Wilcoxon single-rank test in paired comparisons and the t-test
and Mann-Whitney test for independent median comparisons.
Also we used one-way ordinary analysis of variants (ANOVA),
and one-way ANOVA for multiple group comparisons adjusting
the pairwise analyses by Tukey. The relationship between HIV-
1 induction measured according to the expression of p24 and
GFP, and the relationship between the lack of inhibitory receptors
in CD8+ and percentage of killing were assessed using the
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Spearman correlation coefficient. All statistical tests were under
a significance level of 0.05.
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